MarginsXMarginsX
Home › Markets › Health Care › LLY

Eli Lilly and Company (LLY)

LLY trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1431.67
-0.82% on the day
Market cap
$1.35T
Mega cap
Revenue · 2025
$65.2B
+44.7% on 2024
Net income · 2025
$20.6B
31.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerLLY on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000059478
SEC industry codePharmaceutical Preparations
Incorporated inIN

Financials · 2025

LineValue
Revenue$65.2B
Net income$20.6B
Operating incomeNot in SEC XBRL data
Net margin31.7%
Operating marginOperating income not reported
Revenue growth+44.7%
Cash$7.3B
Total assets$112.5B
P/E (computed)65.3×
P/S (computed)20.7×

Warning signs

Cash runway
Cash-flow positive
$4.9B cash at September 30, 2026
Share count, 1 year
-0.5%
2025-10-27 to 2026-10-26 · -0.9% over 3 years
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
-$3.4B
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-29
Cash and burn$4.9B cash; operating cash flow $7.7B a quarter.Report 2026-09-30
Shares outstanding940,745,031 (2026-10-26); 945,383,757 a year earlier; 949,307,237 three years earlier.Cover page 2026-10-26
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2026-06-02
AuditorErnst & Young LLP, Indianapolis, Indiana, United StatesPCAOB Form AP 2026-03-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $3.4B on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$24.4B$6.5B$11.4B$4.9B$49.5B$86.5B10-Q 2026-10-29
Q2 2026
2026-06-30
$23.0B$7.1B$10.7B$8.9B$54.9B$79.7B10-Q 2026-08-05
Q1 2026
2026-03-31
$19.8B$7.4B$5.3B$5.3B$43.4B$72.3B10-Q 2026-04-30
Q4 2025
2025-12-31
$19.3B$6.6B$3.2B$7.3B$42.5B$65.2B10-K 2026-02-12
Q3 2025
2025-09-30
$17.6B$5.6B$8.8B$9.8B$42.5B$59.4B10-Q 2026-10-29
Q2 2025
2025-06-30
$15.6B$5.7B$3.1B$3.4B$39.9B$53.3B10-Q 2026-08-05
Q1 2025
2025-03-31
$12.7B$2.8B$1.7B$3.1B$38.5B$49.0B10-Q 2026-04-30
Q4 2024
2024-12-31
$13.5B$4.4B$2.5B$3.3B$29.5B$45.0B10-K 2026-02-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B22026-05-08
Latest annual report10-K2026-02-12
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-10-29
Latest proxyDEFA14A2026-03-20

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+6.6%
1 month+23.7%
3 months+19.4%
Year to date+34.3%
1 year+41.1%
From 52-week high0.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
JNJJohnson & Johnson$282.55-1.12%$680.2B
ABBVAbbVie Inc.$294.55-0.16%$520.7B
MRKMerck & Company Inc. Common Stock (new)$144.46-2.23%$356.1B
NVSNovartis AG$160.20-0.19%$305.7B
AZNAstraZeneca PLC$184.02-0.23%$285.4B
ABTAbbott Laboratories$107.45-0.99%$186.1B
NVONovo Nordisk A/S$41.60-0.07%$184.2B
PFEPfizer Inc.$28.86-0.10%$164.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier